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ABSTRACT: Background. Primary sinonasal mucosal melanomas are
aggressive tumors with a poor clinical control by current treatments,
raising the urgent need of novel strategies.
Methods. By fluorescence in situ hybridization (FISH), direct sequencing,
and immunohistochemistry, we investigate the spectrum of molecular
abnormalities in a cohort of 32 cases of primary sinonasal mucosal
melanomas.
Results. We found that all primary sinonasal mucosal melanomas lack
BRAF V600E mutation; in addition, they are characterized by somatic
mutations of NRAS (22%) and KIT (12.5%), together with amplification of
RREB1 (100%) and loss of MYB (76%). The large majority of cases
showed KIT protein expression (96.9%). Among tumor suppressor
genes, primary sinonasal mucosal melanomas showed loss of PTEN
(48.1%) and p16/INK4a (55.2%). All tested cases showed expression of
pAkt and pErk, suggesting a combined activation of PI3K/Akt and RAS-
mitogen-activated protein kinase (MAPK) pathways.
Conclusions. This molecular fingerprint strongly argues against the
clinical efficacy of BRAF-inhibitors, but could candidate primary
sinonasal mucosal melanomas to therapeutic strategies targeting RAS
and KIT mutations or inhibiting PI3K-Akt-mTOR pathway. Head Neck 00:
000–000, 2012
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INTRODUCTION
Melanocytes acquire step-wise abnormalities of onco-
genes and tumor suppressor genes during transformation
and neoplastic progression.1 Somatic mutations of onco-
genes such as BRAF, NRAS, HRAS, and GNAQ repre-
sent early events in the development of melanocytic
tumors, primarily by inducing cell proliferation via mito-
gen-activated protein kinase (MAPK) pathway activation.
Abnormalities in tumor suppressor genes contribute to the
dysregulation of additional pathways implicated in mela-
noma progression, including p16-CDK4-RB, ARF-p53,
and PI3K-Akt.2 Recent studies have shown that the fre-
quency of these molecular events are variably distributed
among melanoma subgroups, thus supporting the notion
that melanoma is a molecularly heterogeneous disease.3
For example, melanomas arising on skin intermittently
exposed to the sun (nonchronic sun-damage melanoma)
are characterized by activating mutations of BRAF
(66%)4 and NRAS (15% to 20%)5 with loss of PTEN
expression,6 whereas melanomas arising from mucosal
membrane, acral sites, and chronic sun-damaged skin
(chronic sun-damage melanoma) harbor BRAF mutations
less frequently and show a variable frequency of KIT
mutations,7 together with cyclin D1 (CCND1)8 or cyclin-
dependent kinase 4 amplifications.9 Remarkably, all these
advances have led to the creation of a "molecular disease
model" for melanoma that classifies individual tumors
into molecular subtypes with proposed treatment guide-
lines for each.10
In recent years, efforts have been devoted to identify
driver genetic events leading to transformation of muco-
sal melanocytes. Primary sinonasal tract mucosal mela-
nomas are 1 of the most common mucosal melanomas,
characterized by a very aggressive biologic behav-
ior.11–13 In this study, we took advantage of a homoge-
nous cohort of 32 primary sinonasal tract mucosal mela-
nomas to identify molecular abnormalities relevant to
the biology of this melanoma subtype that could have
also implications for the development of tailored tar-
geted therapies.
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MATERIALS AND METHODS
Patients and tissues
Thirty-two cases of primary sinonasal mucosal melano-
mas diagnosed between May 2003 and August 2010 were
included. Tissue blocks were retrieved from the Depart-
ment of Pathology of 2 institutions (Brescia and Varese
Hospital, Italy). Diagnosis was based on clinical presenta-
tion and pathology findings. Follow-up was available for
all cases. The study on human tissue samples has been
conducted in compliance with the Helsinki Declaration
and with policies approved by the local ethics board
(Spedali Civili di Brescia).
Immunohistochemistry
Tissue sections from formalin-fixed, paraffin-embedded
blocks were used for immunohistochemical staining. The
panel of primary antibodies included MART-1 (mouse,
dilution 1:50; Dako Cytomation, Glostrup Denmark),
HMB45 (mouse, dilution 1:50; Dako Cytomation), tyro-
sinase (mouse, dilution 1:50; NeoMarkers, Fremont, CA),
CD117 (rabbit, dilution 1:50; Dako Cytomation), cyclin
D1 (rabbit, dilution 1:20; Thermo Scientific, Fremont,
CA), p16INK4a (MTM Heidelberg), PTEN (rabbit, dilu-
tion 1:100; Cell Signaling Technology), phospho-Akt
(Ser473) pAkt (rabbit, dilution 1:30 overnight; Cell Sig-
naling Technology), phospho-p44/42 MAPK (Thr202/
Tyr204) pERK (rabbit, dilution 1:250; Cell Signaling
Technology). Upon appropriate antigen retrieval, reactiv-
ity was revealed using the Real EnVision Mouse/Rabbit-
HRP (Dako) or NovoLink Polymer Detection System
(Novocastra) followed by DAB. Immunohistochemical
scores were assessed independently by 2 pathologists
(M.U. and W.V.), according to the percentage of positive
tumor cells (score 0 ¼ absence of positive cells; score 1
¼ 1% to 25% of positive cells; score 2 ¼ 25% to 50% of
positive cells; score 3 ¼ 50% to 75% of positive cells;
and score 4 ¼ >75% of positive cells). Digital images
taken using the Olympus BX60 microscope were captured
using a DP-70 Olympus digital camera and processed
using Analysis Image Processing software (Olympus).
Melanoma multicolor and 9p21 fluorescence in situ
hybridization
Melanoma multicolor fluorescence in situ hybridization
(FISH) (Abbott, Germany) and dual color FISH of the
9p21 region were performed on 27 mucosal melanomas.
For melanoma multicolor FISH and dual color FISH of
the 9p21 region, each series was completed using 1 nega-
tive control (nevus) and 1 positive control (melanoma).
For detection of amplifications or deletions of the
RREB1, MYB, and CCND1 genes in relation to the cen-
tromere of chromosome 6, the melanoma FISH probe
mix (Abbott, Germany) was used consisting of 4 probes:
RREB1 on 6p25, MYB on 6 q23, CCND1 on 11q13, and
CEP6 (centromeric probe of chromosome 6). For the
detection of a deletion of 9p21, a directly spectrum or-
ange (9p21), and spectrum green (centromeric probe of
chromosome 9) labeled probe (Abbott, Wiesbaden, Ger-
many) was used for hybridization.
FISH with the melanoma multicolor and the 9p21 dual
color probe was performed on 3-lM sections of formalin-
fixed, paraffin-embedded tissue after baking at 56C for
16 hours, followed by deparaffinization with xylene and
dehydration with ethanol. All tissue sections were pre-
treated with 1X SSC at 80C for 35 minutes and digested
with pepsin at 37C for 15 minutes. For hybridization
with the 9p21, probe tissue sections were pretreated with
a 30% solution of sodium bisulfite and digested with pro-
teinase K following the instructions of the suppliers (Q-
Biogene, Heidelberg, Germany). Digestion times were
optimized on a case-by-case basis. After a second dehy-
dration step, probes were applied to the tissue sections,
and slides were cover-slipped and sealed with rubber
cement. Sections were heat-denatured and hybridized at
37C for 16 hours. After stringent washing, sections were
counterstained with diamidino-phenylindole I in mounting
medium (1000 ng/mL; Abbott, Wiesbaden, Germany).
A minimum of 30 non-overlapping intact nuclei were
assessed for the presence of amplified and deleted sig-
nals. A deletion was defined as a lower number of signals
compared to the CEP6 signals. Amplification was defined
as 3 or more signals. Nuclei with the appropriate signals
were digitally photographed with a monochrome RT3
CCD camera (Diagnostic Instruments, Sterling Heights,
MI) connected to a Zeiss Axioplan 2 microscope (Zeiss,
Oberkochen, Germany) using a HBO103 lamp and the
appropriate filters (spectrum red, spectrum gold, spectrum
green, spectrum aqua, and 40,6-diamino-2-phenylindole)
for the 5 fluorescence dyes (Zeiss). Reconstruction into a
single image with superimposed blue, red, gold, and
green pseudocolors was accomplished using SPOT soft-
ware (Visitron Systems, Puchheim, Germany). The cutoff
levels for the 4 probes were calculated as described in
the instructions of the supplier and after Gerami et al14 in
2009.
For CCND1 FISH, slides were deparaffinized, dehy-
drated in 100% ethanol, and dried at 45C. Sections were
immersed in HCl (0.2N) for 20 minutes and then incu-
bated in sodium thiocyanate at 81C for 30 minutes.
Slides were placed in pepsin solution (2500–3000 U/mg,
lyophilized) at 37C for 40 minutes and air-dried. The
probe LSI Cyclin D1/CEP11 (Vysis) was applied and
sealed under a cover slip with rubber cement, and incu-
bated at 73C for 5 minutes to denature DNA followed
by hybridization in a humidified chamber at 37C over-
night. The following day, samples were incubated in
post-hybridization solution (2X SSC/0.3% NP-40) at
73C for 2 minutes. Finally, they were air dried and
counterstained with diamidino-phenylindole I/Antifade
solution. Tumor samples were examined with an epifluor-
escent microscope (Nikon, Eclipse 90I). In each sample,
signals were counted in a total of 100 non-overlapping tu-
mor-cell nuclei. The mean signal number of the cyclin
D1 gene as well as CEP was calculated, and the ratio
determined.
DNA extraction and direct sequencing
Formalin-fixed, paraffin-embedded tissue blocks were
reviewed for quality control and tumor content. A repre-
sentative block containing more than 50% of malignant
cells was available for each case. Genomic DNA was
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extracted using the QIAamp DNA FFPE Tissue kit (Qia-
gen). Direct sequencing of KIT (exons 9, 11, 13, 17, 18),
NRAS (exons 2 and 3), BRAF (exon 15), and PI3KCA
(exons 9 and 20) was performed using the Big Dye Ter-
minator v3.1 Cycle Sequencing kit (Applied Biosystems,
Foster City, CA) in accord with the manufacturer’s
instructions for the 3130 Genetic Analyzer. The primers
used for mutational analysis were as follows: BRAF exon
15F 50-TGCTTGCTCTGATAGGAAAATG-30; BRAF
exon 15R 50-AGCATCTCAGGGCCAAAAAT-30; KIT
exon 9F 50-AGCCAGGGCTTTTGTTTTCT-30; KIT exon
9R 50-TGGTAGACAGAGCCTAAACATCC-30; KIT
exon 11F 50-CCAGAGTGCTCTAATGACTG-30; KIT
exon 11R 50-ACCCAAAAAGGTGACATGGA-30; KIT
exon 13F 50-CGGCCATGACTGTCGCTGTAA-30; KIT
exon 13R 50-CTCCAATGGTGCAGGCTCCAA-30; KIT
exon 17F 50-ATGGTTTTCTTTTCTCCTCC-30; KIT exon
17R 50-CAGGACTGTCAAGCAGAGAAT-30; KIT exon
18F 50-CATTTCAGCAACAGCAGCAT-30; KIT exon
18R 50-CAAGGAAGCAGGACACCAAT-30; NRAS exon
2F 50-CAACAGGTTCTTGCTGGTGT-30; NRAS exon
2R 50-CCTCACCTCTATGGTGGGAT-30; NRAS exon
3F 50-GATTCTTACAGAAAACAAGTG-30; NRAS exon
3R 50-ATGACTTGCTATTATTGATGG-30; PI3KCA
exon 9F 50-GCTTTTTCTGTAAATCATCTGTG 30;
PI3KCA exon 9R 50-CTGAGATCAGCCAAATTCAGT-
30; PI3KCA exon 20F 50-CATTTGCTCCAAACT-
GACCA-30; PI3KCA exon 20R 50-CAATTCCTATG-
CAATCGGTCT-30. Mutations were confirmed with a sec-
ond DNA extraction on a different level of the tissue
block.
Statistical analysis
SPSS v 10.0.1, 1999 (SPSS, Chicago, IL) was adopted
and survival estimates were calculated by the
Kaplan–Meier method. Univariate comparisons between
groups were performed using the log-rank test. Any p val-
ues < .05 were considered statistically significant.
RESULTS
Primary sinonasal mucosal melanomas are aggressive
melanomas with high propensity to distant spreading
The main clinical and pathological findings of the
patients are summarized in Table 1. Patients (17 men and
15 women) ranged in age from 35 to 88 years (mean,
69.5 years). All tumors originated in the sinonasal tract:
TABLE 1. Clinical and pathological findings of primary sinonasal mucosal melanomas.
Case Sex
Age,
y Site Histology
Previous
treatment Treatment
TNM
classification
Adjuvant
therapy
Relapse
site
Time to
relapse, mo
Relapse
treatment
Follow-up,
mo Status
#1 F 68 M E  CFR T3 N0M0  MB 2  7 DOD
#2 M 63 NE E  CFR T3 N0M0 RT   NA 94 NED
#3 M 77 M E  CHT T3 N0M1 NA ML 11 CHT 13 DOD
#4 F 88 NE E  ERTC T3 N0M0  T 24 S, RT 59 DOD
#5 M 64 M E, S  CFR T4aN0M0  T, MB,L 6  9 DOD
#6 F 71 NE E  ERTC T3 N0M0  T, MSK,L 17 S, CHT 79 AWD
#7 F 67 NE E  CER T3 N0M0  T, MLI 15 S, RT 19 DOD
#8 F 76 NE E  CER T3 N0M0  MB,L 22  25 DOD
#9 F 85 NE E  CER T3 N0M0  T, MB,L 18  20 DOD
#10 F 70 NE E  CFR T4aN0M0  N, MG 22 S, RT 34 DOD
#11 F 80 NE E S ERTC T3 N0M0    NA 52 NED
#12 F 56 NE E  CER T4bN1M0 CHT T, N 5  9 DOD
#13 M 81 M E  CFR T3 N0M0  N, MAG 29  29 DOD
#14 M 60 NE E S ERTC T3 N0M0    NA 38 NED
#15 M 76 NE E  CER T4aN0M0  T, MT 5 CHT 10 DOD
#16 M 59 NE E CHT CER T4bN2bM0  T, ML 9 S 11 DOD
#17 F 64 NE E S, CHT CER T4bN0M0 RT T, ML,AG 1 CHT 11 DOD
#18 F 73 NE E  ERTC T4aN0M0    NA 21 NED
#19 M 79 NE E  ERTC T4bN0M0  T, ML 4  7 DOD
#20 F 49 NE E, S  ERTC T4bN0M0 CHT T, ML 1 CHT 17 AWD
#21 M 85 M E  ERTC T4aN0M0  T 8 S 8 DOD
#22 F 71 NE E  ERTC T4bN0M0  T 1  3 DOD
#23 M 35 NE E, S S CER T4aN0M0 CHT,RT ML,B,BO 12  16 DOD
#24 F 79 NE E S ERTC T3 N0M0  ML,P,PA,K,BO 1 CHT 33 AWD
#25 M 53 M E  CHT T4bN0M1 NA ML,P,BO 10 CHT 29 DOD
#26 M 78 NE E  ERTC T3 N0M0  T, MB,L 3  10 DOD
#27 M 54 M S  ERTC T4aN0M0  ML 1 CHT 7 DOD
#28 M 84 M E  ERTC T3 N0M0  T, ML,LI 5 S 22 DOD
#29 M 81 NE E  ERTC T3 N1M0  T, MB,L 5 S 34 DOD
#30 M 76 NE E  ERTC T3 N0M0  T, N, ML 6 S 21 DOD
#31 F 70 M E  CHT T3 N0M1 NA ML,P,PA,K,BO 1 CHT 20 DOD
#32 M 51 NE E  ERTC T4aN0M0    NA 19 NED
Abbreviations: M, maxillary sinus; E, epithelioid morphology; CFR, craniofacial resection; DOD, dead of disease; NE, nasoethmoidal complex; RT, radiotherapy; NA, not applicable; NED, no evi-
dence of disease; CHT, chemotherapy; ERTC, endoscopic resection with transnasal craniectomy; T, trachea; S, spindle cells morphology; AWD, alive with disease; CER, cranioendoscopic resec-
tion; S, surgery; P, pleura; B, brain; L, lung; SK, skin; LI, liver; G, gut; AG, adrenal glands; BO, bone; PA, pancreas; K, kidney.
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23 (71.9%) in the naso-ethmoidal complex and the
remaining 9 (28.1%) in the maxillary sinus. In accord
with the 2010 Union Internationale Contre le Cancer
Staging System, primary lesions were classified as fol-
lows: 17 cases (53.1%) pT3; 8 (25%) pT4a; and 7
(21.9%) pT4b. Twenty-nine patients (90.6%) underwent
surgery tailored to the extension of disease (Table 1).
Neck dissection was performed only in 3 patients and
planned according to the nodal metastasis features (local-
ization, size, number, and possible extracapsular exten-
sion). Three patients (9.4%) with maxillary melanoma
were not considered amenable for surgical excision due
to the presence of distant metastases at diagnosis and
were treated with palliative chemotherapy.
Follow-up ranged between 3 and 94 months (mean,
24.6 months) and was available in all cases. The three
patients treated with palliative chemotherapy developed
uncontrolled spreading of their disease and died of dis-
ease in a short period (mean, 20.6 months). Among the
29 surgically treated patients, 24 (82.7%) experienced 1
or more recurrences. In 17 of 29 patients (58.6%), a local
relapse was identified, whereas regional and distant fail-
ure occurred in 4 of 29 (13.8%) and 20 of 29 (68.9%)
cases, respectively. Sites of distant failure were broadly
distributed: lung in 18 of 32 cases (56.2%); brain in 7 of
32 (21.9%); bone in 4 of 32 (12.5%); pleura in 3 of 32
(9.4%); adrenal glands, liver, kidney, and pancreas in 2
of 32 cases (6.2%) each; and skin, trachea, and gut in 1
case each (3.1%).
At the last follow-up, performed in December 2011, 24
of 32 patients (75%) had died of disease in a period rang-
ing from 3 to 59 months (mean survival, 18 months),
mainly for metastatic spread of disease. The remaining 8
patients were alive, 3 of 32 (9.4%) with disease and 5 of
32 (15.6%) free of disease. The 5-year overall survival of
the patient cohort was 25.8 6 14.9%. These data confirm
the highly aggressive behavior of this neoplasm15 with an
urgent need of alternative strategies for treatment.16
Primary sinonasal mucosal melanomas is characterized
by occurrence NRAS and KIT mutations, and the lack of
BRAF V600E
By direct sequencing, we analyzed our cohort of pri-
mary sinonasal mucosal melanomas for BRAF, NRAS,
and KIT mutations in "hot-spot" coding exons (Table 2
and Figure 1). The majority of cases lacked BRAF muta-
tions in exon 15 (31/32; 97%); 1 case (case 7) harbored a
D594G mutation. The classic BRAF V600E mutation was
not found in any cases. Conversely, NRAS mutations
where found in 7 of 32 cases (22%). Of these, 3 (42.8%)
involved codon 61 (cases 10, 13, and 24), whereas the
remaining 4 were found on codons 12 (28.5%; cases 30
and 32) and 13 (28.5%; cases 20 and 21). We screened
all primary sinonasal mucosal melanomas for KIT muta-
tions in exons 9, 11, 13, 17, and 18. In 4 of 32 cases
(12.5%), we found KIT mutations in exon 11 (cases 5,
15, and 25) and exon 18 (case 11).
By immunohistochemistry, KIT protein expression
(score 1–4) was found in 31 of 32 cases (96.9%; Table
3 and Figure 2). The majority of cases (19 of 32;
59.4%) showed diffuse and intense (score 3 and 4) KIT
reactivity. Where present, the intraepithelial component
of the tumor was also positive (8 of 10 cases; 80%). By
analyzing the subcellular localization of the KIT pro-
tein, we found that 12 of 32 cases (37.5%) showed dif-
fuse cytoplasmic and membrane staining, whereas in 18
of 32 cases (56.2%) KIT expression was limited to the
cytoplasm of tumor cells; in 1 of 32 cases (3.1%) stain-
ing was confined to the tumor cell membrane. Among
the 4 primary sinonasal mucosal melanomas with so-
matic mutations of the KIT gene, 3 cases (cases 5, 15,
and 11) showed strong and diffuse protein expression,
whereas in 1 case (case 25) reactivity was weak, cyto-
plasmic, and limited to a minor portion of the tumor.
Primary sinonasal mucosal melanomas shows
amplification of RREB1 and loss of MYB, but lack
CCND1 amplification
A recently published probe combination for RREB1/
LSI, MYB/LSI, and CCND1/CEP6 can be used to detect
chromosomal and gene aberrations commonly found in
cutaneous melanomas.14 These abnormalities are repre-
sented by increased copy number of CCND1 (11q13)
and RREB1 (6p25) followed by 6q23 loss relative to
CEP6. A commercially available 4-color FISH assay
has demonstrated high sensitivity and specificity in
detecting these abnormalities in cutaneous melano-
mas.17 Seventeen of the primary sinonasal mucosal mel-
anomas cases in our cohort were suitable for FISH anal-
ysis (Table 4 and Figure 3A and 3B). The overall
sensitivity of the assay was 100% (with at least 1 alter-
ation detected). In particular, all cases showed gain of
6p25 (RREB1; all of 17; 100%), whereas loss of 6q23
(MYB) was present in 76% of cases (13 of 17). Gain of
CCND1 (11q13) was observed in 1 case (1 of 17; 5.8%;
case 22) only with Gerami criteria14 (Table 4). These
data suggest that chromosomal and genetic abnormal-
ities detected in cutaneous melanomas by the melanoma
FISH approach can also be observed in primary sino-
nasal mucosal melanomas. Interestingly, a very similar
profile (high rate of 6p25 gain and 6q23 loss) is found
in the acro-lentiginous (AL) subgroup.17 However, com-
pared to the AL subgroup, the primary sinonasal muco-
sal melanomas lacked CCND1 gene amplification, as
confirmed on 6 over-expressing cases (cases 2, 3, 9, 14,
TABLE 2. Mutational analysis of primary sinonasal mucosal melanomas.
Gene Exon cDNA Protein Case
KIT 11 1671G>C W557C #5
11 1727T>C L576P #15
11 1672A>G K558E #25
18 2591C>T S864F #11
NRAS 2 37G>T G13C #20
2 38G>A G13D #21
2 35G>A G12D #30
2 35G>C G12A #32
3 182A>T Q61L #10
3 182A>G Q61R #13
3 182A>G Q61R #24
BRAF 15 1781A>G D594G #7
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16, and 22) by using an alternative FISH assay with a
centromeric probe for chromosome 11. However, a
large proportion of cases (65.6%, score >1), including
those tested with the melanoma FISH, showed overex-
pression of Cyclin D1 by immunohistochemistry (Table
3 and Figure 3C and 3D).
Loss of tumor suppressor genes PTEN and p16
in primary sinonasal mucosal melanomas
Loss of tumor suppressor genes expression involving
PTEN and INK4a has been variably detected in sporadic
cutaneous melanoma.2,18 Using immunohistochemistry,
we examined the expression of PTEN and p16/INK4a in
FIGURE 1. Somatic mutation of NRAS (A and B) and KIT (C and D) in primary sinonasal mucosal melanomas. Black arrows indicate NRAS
mutations affecting exon 2 (G13C, case 20 in A) and 3 (Q61R, case 13 in B) and KIT mutations in exon 11 (W557C, case 5 in C; L576P, case 15 in
D). A corresponding wild-type sequence is shown in each of the 4 panels. [Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
TABLE 3. Summary of immunohistochemical staining of primary sinonasal mucosal melanomas.
Marker
Score
0 1 2 3 4
KIT 1/32 (3.1%) 5/32 (15.6%) 7/32 (21.9%) 7/32 (21.9%) 12/32 (37.5%)
CCND1 5/32 (15.6%) 6/32 (18.8%) 5/32 (15.6%) 11/32 (34.4%) 5/32 (15.6%)
PTEN 9/27 (33.3%) 2/27 (7.4%) 2/27 (7.4%) 8/27 (29.6%) 6/27 (22.2%)
p-16 2/29 (6.9%) 6/29 (20.7%) 8/29 (27.6%) 0/29 (0%) 13/29 (44.8%)
pERK 0/27 (0%) 3/27 (11.1%) 3/27 (11.1%) 18/27 (66.7%) 3/27 (11.1%)
pAkt 0/29 (0%) 3/29 (10.3%) 0/29 (0%) 5/29 (17.3%) 21/29 (72.4%)
Notes: Score 0 ¼ absence of positive cells; score 1 ¼ 1% to 25% of positive cells; score 2 ¼ 25% to 50% of positive cells; score 3 ¼ 50% to 75% of positive cells; score 4 ¼ >75% of positive
cells.
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our cohort of primary sinonasal mucosal melanomas. The
expression was variable from case to case, and showed
tumor heterogeneity even within individual tumors (Table
3 and Figure 4A–4D). In particular, loss of PTEN expres-
sion (<50% of positive cells; score 0–2) was observed in
13 of 27 cases (48.1%) with a total absence of the protein
(score 0) in 9 of 27 cases (33.3%). CDKN2A generates at
least 3 structurally and functionally unrelated transcrip-
tional variants that include p16/INK4a, p14ARF, and p12.
Loss of p16 protein in primary sinonasal mucosal
FIGURE 2. Expression of KIT (CD117) in primary sinonasal mucosal melanomas. CD117 expression is found in intraepithelial and infiltrating
primary sinonasal mucosal melanomas cells (A). The staining pattern of CD117 ranges from a strong membrane (A and B) or cytoplasmic (C) signal
to weak or absent expression (D). For immunohistochemistry, sections were counterstained with Meyer’s hematoxylin and secondary antibodies
revealed with DAB (brown). Original magnification 100 (A) and 600 (B–D). [Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
TABLE 4. Details on melanoma fluorescence in situ hybridization following Abbott and Gerami criteria.
Case
Abbott/Germany Gerami et al., 2009
Nuclei abnormal
for RREB1 (6p25)
signals: 63%
Average MYB
(6q23) signals for
nucleus: 2.5%
Loss in MYB
(6q23) relative
to CEP6: 31%
Average CCND1
(11q13) signals for
nucleus: 2.5%
Gain in RREB1
(6p25):>29%
Gain in RREB1
(6p25) relative
to CEP6: >55%
Loss in MYB
(6q23) relative
to CEP6: >40%
Gain in
CCND1
(11q13): >38%
#2 100% 2.16% 76.60% 2.23% 100% 66.30% 76.60% 33.30%
#3 96.60% 1.63% 16.60% 1.70% 96.60% 100% 16.60% 10%
#7 100% 1.36% 90% 1.30% 100% 66.60% 90% 0%
#9 80% 1.56% 50% 2.23% 80% 63.30% 50% 33.30%
#12 100% 2.13% 43.30% 1.66% 100% 76.60% 43.30% 13.30%
#14 56.60% 2.30% 10% 2.06% 56.60% 50% 10% 13.30%
#15 100% 1.56% 70% 2.20% 100% 50% 70% 36.60%
#16 100% 2% 86.60% 1.93% 100% 43.30% 86.60% 23.30%
#19 100% 1.36% 40% 1.23% 100% 83.30% 40% 0%
#22 96.60% 2.60% 13.30% 2.10% 96.60% 80% 13.30% 40%
#24 100% 2.00% 70% 1.80% 100% 86.60% 70% 3.33%
#25 100% 2.20% 36.60% 1.50% 100% 86.60% 36.60% 3.33%
#26 96.60% 1.06% 26.60% 1.36% 96.60% 100% 26.60% 3.33%
#27 96.60% 1,23% 70% 1,6% 96.60% 76.60% 70% 0%
#30 100% 1.16% 50% 1.13% 100% 100% 50% 0%
#31 100% 1.16% 63.30% 1.63% 100% 76.60% 63.30% 3.33%
#32 96.60% 1.83% 50% 1.36% 96.60% 76.60% 50% 0%
Note: Values over the cut-off are in bold face.
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melanomas is associated with 9p21 deletion by FISH.19
In our cohort of primary sinonasal mucosal melanomas,
loss of p16/INK4a in more than 50% of tumor cells
(score 0– 2) was observed in 16 of 29 cases (55.2%);
however, among these, only 2 showed complete loss
(score 0) of the protein. We performed FISH analysis on
the 9p21 region. Fifteen cases were suitable for signal
interpretation. Of these, only 3 tumors (cases 20, 26, and
30) showed heterozygous deletion of 9p21 including the 2
cases completely lacking p16 protein (insert in Figure
4B). By combining these data, we found that although
heterogeneously, lack of at least 1 tumor-suppressor gene
(score 2) was present in the large majority of cases (24
of 29; 82.7%), whereas combined loss of p16 and PTEN
(5 of 27; 18.5%) represented a more rare event. In addi-
tion, complete loss (score 0) of a tumor-suppressor gene
was a mutually exclusive event, because only 1 of 27
cases (3.7%) showed combined complete loss of both
PTEN and p16 (case 28).
Activation of PI3K-Akt and RAS-MAPK pathways is a
common event in primary sinonasal mucosal
melanomas
Among relevant pathways sustaining melanoma cell
survival, proliferation, and invasion, activation of PI3K-
Akt and RAS-MAPK are the best characterized.2,18 The
availability of antibodies recognizing the phosphorylated
forms Akt and ERK on fixed tissues allows direct testing
of the activation of PI3K-Akt and RAS-MAPK pathways
on tumor cells. Our cohort of primary sinonasal mucosal
melanomas was analyzed for the expression of pAkt and
pERK by immunohistochemistry (Table 3 and Figure 4E
and 4F). Interestingly, all cases (all of 29) were positive
for pAkt expression and, when scored based on the per-
centage of positive tumor cells, the level of heterogeneity
for this marker was very low. In particular, strong and
diffuse pAkt expression (score 3 and 4) was very com-
mon (26 of 29; 89.7%), whereas in 3 of 29 cases (10.3%,
score 1) positive pAkt staining was seen in less than 25%
of tumor cells (score ¼ 1). The pAkt activation in cancer
might depend on PTEN loss or activating mutations of
PI3KCA which encode for the main catalytic subunit of
the phosphatidylinositol 3-kinases. By analyzing 9 cases
of primary sinonasal mucosal melanomas (cases 1, 3, 6,
8, 9, 12, 14, 16, 19), including 3 cases with preserved
PTEN expression, no mutations in the exons 9 and 20 of
PIK3CA were found. Similar to pAkt, all cases (all of 27)
stained for pERK. The staining pattern was strong and
diffuse (score 3 and 4) in a large proportion of cases (21
of 27; 77.8%), whereas in the remaining cases (6 of 27,
22.2) less than 50% of tumor cells were positive (score 1
and 2).
Taken together, these data indicate that the PI3K-Akt
and RAS-MAPK pathways are commonly activated in
primary sinonasal mucosal melanomas. In particular, this
FIGURE 3. Melanoma fluorescence in situ hybridization (FISH) and CCDN1 expression in primary sinonasal mucosal melanomas. A FISH image (A)
with the corresponding box plot (B) of a prototypical primary sinonasal mucosal melanomas case (case 2) showing gain of RREB1, loss of MYB
relative to CEP6 and normal CCND1. Two examples of primary sinonasal mucosal melanomas showing diffuse (score 4) and absent (score 0)
CCND1 expression are shown in (C) and (D), respectively. For immunohistochemistry, sections were counterstained with Meyer’s hematoxylin and
secondary antibodies revealed with DAB (brown). Original magnification 600 (A) and 400x (B–D). [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
MOLECULAR PROFILE OF SINONASAL MUCOSAL MELANOMA
HEAD &NECK—DOI 10.1002/HED MONTH 2012 7
occurs either in cases with constitutive activation of the
pathway due to mutation in known oncogenes (KIT,
NRAS, and BRAF), but also in other cases where the
pathway inducer is still unknown.
Clinical correlations
To verify the prognostic significance of the major mo-
lecular abnormalities detected in primary sinonasal muco-
sal melanomas, we performed a survival analysis of dif-
ferent primary sinonasal mucosal melanoma subgroups.
In terms of 5-year overall survival, no significant differ-
ences were observed with regard to occurrence of NRAS
mutations (33.3 6 25.5% vs 30.7 6 17.3%; p ¼ .32),
KIT mutations (25 6 21.7% vs 31.6 6 17.1%; p ¼ .51),
loss of PTEN in >50% of tumor cells (37.5 6 28.6% vs
18.6 6 15.9%; p ¼ .09), and loss of p16/INK4a in >50%
of tumor cells (21.8 6 18.5% vs 27.5 6 22.8%; p ¼
.71).
DISCUSSION
In this study, we report a detailed clinical and molecu-
lar analysis of a homogenous cohort of 32 cases of pri-
mary sinonasal mucosal melanomas. Our series confirms
previous studies15 indicating that primary sinonasal muco-
sal melanomas is an aggressive melanocytic neoplasm
characterized by a high tendency to recur and to metasta-
size at various distant sites. This behavior depends on the
significant delay in diagnosis and on the intrinsic high
aggressiveness of the tumor.20,21 The mainstay for treat-
ment of primary sinonasal mucosal melanomas continues
to be the surgical excision, with the endoscopic-assisted
approaches that prove to be a safe and feasible procedure
alternative to open surgery, with reduced morbidity and
FIGURE 4. Expression of p16, PTEN, pERK, and pAkt in primary sinonasal mucosal melanomas. Representative primary sinonasal mucosal
melanomas cases showing expression of PTEN (score 4 in A and score 0 in B), p16 (score 4 in C and score 0 in D), pERK (score 4 in E), and pAkt
(score 4 in F). Lack of a signal for p16 in case 20 is associated with 9p21 deletion by fluorescence in situ hybridization (FISH; insert in D). For
immunohistochemistry, sections were counterstained with Meyer’s hematoxylin and secondary antibodies revealed with DAB (brown). Original
magnification 400 (A–F) and 600 (insert in B). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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comparable results. At the present time, no significant
improvement in survival can be obtained by systemic16
and local adjuvant treatment in primary sinonasal mucosal
melanomas.22–27
Although the molecular-driven stepwise transformation
of melanocytes has been extensively documented in cuta-
neous melanoma,1 much less is known about the rarer
and more aggressive forms of primary mucosal mela-
noma, including primary sinonasal mucosal melanomas.
We found that primary sinonasal mucosal melanomas are
characterized by the occurrence of mutually exclusive so-
matic mutations of NRAS (22%) and KIT (12.5%),
TABLE 5. KIT mutations in melanoma subtypes reported in the literature.
Reference
Mucosal Melanoma
Acral melanoma, Chronic sun-damage melanoma,
Frequency (rate)
Site, no. of
patients
Exon, no. of
patients Frequency (rate) Frequency (rate)
Curtin7 8/38 (21%) NOS 11 (4) 3/28 (11%) 3/18 (16.7%)
13 (3)
18 (1)
Antonescu40 3/20 (15%) AN (3) 11 (3) – –
Rivera39 4/18 (22.2%) OCA (4) 11 (2) – –
13 (2)
Satzger41 6/37 (16%) HN (2) 11 (5) – –
GU (3) 18 (1)
AN (1)
Beadling42 7/45 (15.6%) HN (3) 11 (6) 3/13 (23%) 1/58 (1.7%)*
AN, GU (4) 17 (1)
Carvajal46 12/45 (27%) NOS NOS 5/22 (23%) 0/13 (0%)
Torres–Cabala45 9/52 (17%) AN (3) 11 (6) 5/39 (12.8%) –
GU (4) 13 (2)
OCA (1) 17 (1)
OCU (1)
Ashida29 0/6 (0%) – – 2/22 (9%) –
Handolias43 6/16 (37.5%) AN (4) 11 (3) 1/16 (6%) –
GU (1) 17 (2)
OC (1) 13 (1)
Kong44 16/167 (9.6%) NOS 11 (9) 23/193 (11.9%) 6/29 (20.7%)
13 (2)
17 (4)
18 (1)
This report 4/32 (12.5%) SN (4) 11 (3) – –
18 (1)
Abbreviations: NOS, not otherwise specified; AN, anal; OCA, oral cavity; HN, head and neck; GU, genitourinary tract; OCU, ocular; SN, sinonasal.
* Cutaneous melanoma subtype not specified.
TABLE 6. Treatment of patients with KIT-mutated metastatic melanoma with tyrosine-kinase inhibitors reported in the literature.
Reference
No. of
patients Melanoma type KIT (IHC) KIT abnormalities Agent Dose, mg/d Clinical response
Lutzky47 1 Mucosal þ K642E Imatinib 400–600 CR
Hodi48 1 Mucosal þ ex 11* Imatinib 400 CR
Quintas–Cardama49 1 Mucosal þ V560A Sorafenib 800 CR
Carvajal46 5 Acral and mucosal þ 3 pts: ex 11† Imatinib 300–800 3 pts: PR
2 pts: SD1 pt: ex 11‡ Imatinib
1 pt: ex 13† Imatinib
Woodman50 2 þ L576P Dasatinib 140 PR
Zhu53 1 Mucosal þ V559A Sunitinib 37.5 PR
Kluger51 2 Acral and mucosal þ 1 pt: K642E Dasatinib 140 1 pt: PR
1 pt: ex 11§ Dasatinib 1 pt: NR
Satzger52 1 Mucosal þ L576P Imatinib 400 SD
Handolias43 4 Mucosal þ 1 pt: ex 11* Imatinib 600 PR
1 pt: K642E Imatinib 400 PR
1 pt: L576P Imatinib 400–600 PD
1 pt: D820Y Sorafenib 400 SD
Abbreviations: IHC, immunohistochemistry; CR, complete response; PR, partial response; SD, stable disease; NR, no response; PD, progressive disease.
* Duplication.
†Mutation not otherwise specified.
‡ Amplification.
§Deletion.
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associated with amplification of RREB1 (100%), loss of
MYB (76%), and variable loss of tumor suppressor genes,
including PTEN (48.1%) and p16/INK4a (55.2%). These
abnormalities might lead to diffuse activation of PI3K/
Akt and RAS-MAPK pathways, as shown by immuno-
staining for pAkt and pERK. Remarkably, this profile is
partially shared by mucosal melanoma from other sites
and by AL group.28,29
Similarly to other mucosal melanoma and AL/mucosal,
primary sinonasal mucosal melanomas lack the V600E
mutation in the BRAF gene, which is instead a very com-
mon somatic event in nonchronic sun-damage cutaneous
melanoma.3,30–32 This finding strongly argues against the
clinical efficacy of the recently introduced RAF inhibitor
in primary sinonasal mucosal melanomas.33 Notably, we
detected a D594G substitution of the BRAF gene in only
1 case. This mutation has been previously characterized
in melanoma cell lines and compared to the V600E mu-
tant, D594G is a low-activity mutant that signals through
CRAF and is sensitive to Sorafenib.34
NRAS mutations were found in 22% of cases and
involved codons 12, 13, and 61. This mutation rate is
similar to nonchronic sun-damage melanoma.2 Recently,
NRAS mutations have also been reported in mucosal mel-
anoma arising from different sites.31,35 Although molecu-
lar strategies targeting mutant RAS have not been very
successful,36,37 recently it has been reported that effica-
cious targeting of NRAS-driven cutaneous melanomas
can be obtained by simultaneous silencing of multiple
RAS effectors, including BRAF, CRAF, and PIK3CA.38
In keeping with recent data that showed that activating
mutations of the KIT gene occur with variable frequency in
mucosal melanoma and cutaneous melanoma (Table
5),7,29,39–46 we found KIT mutations in 12.5% of primary
sinonasal mucosal melanomas cases. KIT mutations have
been observed in 9.6% of mucosal melanoma and repre-
sented an adverse prognostic factor for overall survival.44
Interestingly, KIT mutated mucosal melanomas are sensi-
tive to tyrosine kinase inhibitors (TKis) (Table 6).43,46–53
All the KIT mutations found in our cohort of primary sino-
nasal mucosal melanomas are activating and located in the
juxta-membrane region (exon 11; W557C, K558E, and
L576P) or in the TK2 domain (exon 18; S864F) of the ty-
rosine-kinase receptor. K558E and S864F mutations are
very rare in human cancers.54,55 Substitutions in codon 557
are very common and sensitive to TKis in patients with
gastrointestinal stromal tumors (GIST),56 although the spe-
cific W557C substitution has been detected in only 2
patients with GIST57 and in a single case of intracranial
germinoma.58 L576P mutation is the most common muta-
tion in melanoma and shows sensitivity to TKi,40 especially
to dasatinib.50 In GIST, KIT mutations are commonly asso-
ciated with protein overexpression by immunohistochemis-
try59,60; however, protein overexpression alone is not suffi-
cient to predict clinical response to TKi and the selection
of candidates for TKi should be based on mutational status
of the KIT gene.61 Similarly, KIT overexpression in mela-
nomas cannot predict sensitivity to TKi.62 In our series, the
immunohistochemical staining for KIT has low sensitivity
(75%), very low specificity (42.8%), poor positive predic-
tive value (15.8%), and significant negative predictive
value (92.3%) in detecting mutations.
Significantly, we observed that all primary sinonasal
mucosal melanomas were identified by using a novel
FISH panel which include 3 locus-specific identifier
(RREB1, MYB, and CCND1) genes. In particular primary
sinonasal mucosal melanomas, similarly to the cutaneous
counterpart, shows a high frequency of gain of 6p25 and
loss of 6q23. Conversely, gain of 11q13 (CCND1), which
is reported in more than 30% of cutaneous melanomas
including the AL/mucosal subtype,8,63 was not observed
in primary sinonasal mucosal melanomas. However, over-
expression of CCND1 protein (> score 1) was present in
65.6% of primary sinonasal mucosal melanoma cases.
Although limited to a single cell line of metastatic mela-
noma overexpressing cyclin D1, silencing of the CCND1
gene by antisense oligonucleotides resulted in significant
suppression of tumor growth even in the absence of gene
amplification.64 Although data require further validation,
they could help identify a novel targeting strategy for pri-
mary sinonasal mucosal melanomas.
Data on the role of tumor suppressor genes in mucosal
melanoma transformation and progression are inconclu-
sive. We report that among tumor suppressor genes, a
significant fraction of primary sinonasal mucosal melano-
mas have lost PTEN (48.1%) and p16 (55.2%), with total
absence of the protein in 33.3% and 6.8% of the cases,
respectively. Loss of PTEN together with activating
mutations of PIK3CA are the major molecular events
leading to the hyperactivation of PI3K-Akt pathway in a
wide variety of human neoplasms.65 In our cohort of pri-
mary sinonasal mucosal melanomas, the diffuse hyperac-
tivation of PI3K-Akt pathway, as proved by the expres-
sion of pAkt (recognizing the phosphorylated Ser473
residue),66 was found in 89.7% of cases. This result,
which can be explained in a fraction of cases by PTEN
loss, is not dependent on activating mutations of
PIK3CA. Although these findings require further investi-
gation at the genetic and epigenetic levels, they clearly
indicate that activation of PI3K-Akt might sustain pri-
mary sinonasal mucosal melanomas progression. Strat-
egies to inhibit PI3K-Akt-mTOR pathway at multiple lev-
els are currently in clinical trials and might represent a
promising tool also for melanomas.67 Our findings indi-
cate that the immunohistochemical demonstration of pAkt
expression and PTEN loss might identify responders to
PI3K-Akt-mTOR inhibitors.
To our knowledge, this is the largest series of primary
sinonasal mucosal melanomas subjected to a comprehen-
sive analysis of the molecular abnormalities in oncogenes
and tumor suppressor genes. We found that primary sino-
nasal mucosal melanomas are characterized by a complex
array of abnormalities leading to diffuse activation of the
PI3K/Akt and RAS-MAPK pathways. The occurrence of
these abnormalities does not represent a prognostic factor
in terms of patient survival; however, large-scale studies
are mandatory to this end. Significantly, early somatic
events (KIT, NRAS, and BRAF mutations) are observed
only in a relatively small fraction of primary sinonasal
mucosal melanomas. This suggests that additional,
unknown abnormalities might drive or cooperate in sun-
light-independent melanoma genesis. On the other hand,
the consistent finding of KIT protein expression in pri-
mary sinonasal mucosal melanomas indicate that the
TURRI–ZANONI ET AL.
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activation of PI3K/Akt and RAS-MAPK pathways might
also rely on ligand-dependent activation of this receptor.
On the evidence that effective and durable molecular tar-
geting approaches require inhibition of multiple pathway
check points,68,69 our data might have implications for
the development of tailored therapies for primary sino-
nasal mucosal melanomas.
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